Covagen raises $63m for targeted antibody work
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged ANTI TNF/IL-17A, antibody, Ascent Biomedical Ventures, Avi Kometz, bispecific, COVA322, Covagen, Dr Dragan Grabulovski, Dr Julian Bertschinger, Dr Karl Naegler, Edmond de Rothschild], Elias Papatheodorou, ETH Zurich, Fynomers, Gimv, Investment, Medigene, Merck Serono, Micromet, Mitsubishi Tanabe Pharma Corporation, MP Healthcare Venture Management, Novartis Venture Fund, Prof Christoph Lengauer, Roche, Seroba Kernel Life Sciences, Sir Greg Winter, Third Rock Ventures, trispecific, Ventech, venture capital
Leave a comment
Symphogen’s Monoclonal Antibody Technology Making Waves
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged ADC, antibody drug conjugate, clinical trials, conjugated mAb, epidermal growth factor receptor, Essex Woodland, European Society of Hematology, Genentech, hematology, Kirsten Drejer, Medicon Valley, Merck, monoclonal antibody, Novo A/S, oncology, Phase II, PKA, Roche, squamous cell carcinoma of the head & neck, SYM004, Symphogen
Leave a comment
Merus Biopharmaceuticals building to future with strong pipeline
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Acute Myeloid Leukaemia, Affitech, Aglaia Biomedical Ventures, Amsterdam Biotech, Astellas, Bay City Capital, bispecific, Charity, Crucell, Dr Setareh van Driel Shamsili, European Society of Hematology, funding, government, hematology, IND, Johnson & Johnson, Life Science Partners, London Biotech, London Innovation Centre, MCLA-117, Merus Biopharmaceuticals, Mr Jason Avery, Netherlands, Novartis Venture Fund, oncology, Pfizer, Series B funding, Ton Logtenberg
Leave a comment
Billionaires send Ganymed racing through clinic
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases
Tagged ADC, Andreas Strungmann, ATS Beteiligungsverwaltung GmbH, BioRN, bispecific, clinical studies, Dr Ozlem Tureci, EMA, FDA, Ganymed, gastroesophageal cancer, Hexal, IMAB362, IMABs antibodies, Novartis, orphan drug designation, Professor Uger Sachin, Thomas Strungmann, venture capital
Leave a comment
CFO appointments no longer just a numbers game
Authored by Karl Simpson
Posted in General, Pharmaceutical business, Recruitment Market
Tagged Asia, AstraZeneca, biotechnology, board, CEO, CFO, Chairman, europe, external communication, financial technocrats, globalising, IPO, Liftstream, management, Marc Dunoyer, Pascal Soriot, private biotechs, public company, Rare Disease, regulatory, venture capital
Leave a comment
Open Innovation could spur diversity
Authored by Karl Simpson
Posted in General, Pharmaceutical business, Workplace Diversity
Tagged Berkeley, biomarkers, biotechnology, business, china, Diversity, Finland, Haas Business School, Henry Chesbrough, innovation, innovation black hole, Karl Simpson, manufacturing, medicine, Open Innovation, pharmaceutical executive, pharmaceuticals, R&D, research, research and development, South America, University of California
Leave a comment
Diversity agenda still lagging in the biotechnology market
Authored by Karl Simpson
Posted in General, Recruitment Market, Workplace Diversity
Tagged 2013, Belén Garijo, biotech, biotechnology, Board room, Burberry, CEO, Christopher Baily, Diversity, Executive Team, Gender Gap, General Counsel, Human Resources, Liftstream, Merck Serono, pharmaceutical, regulatory affairs, Scandinavian, WEE, women, World Economic Forum
Leave a comment
